Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최한곤 | - |
dc.date.accessioned | 2018-02-22T00:29:15Z | - |
dc.date.available | 2018-02-22T00:29:15Z | - |
dc.date.issued | 2015-09 | - |
dc.identifier.citation | JOURNAL OF CONTROLLED RELEASE, V. 214, Page. 30-39 | en_US |
dc.identifier.issn | 0168-3659 | - |
dc.identifier.issn | 1873-4995 | - |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0168365915300262 | - |
dc.identifier.uri | http://hdl.handle.net/20.500.11754/39286 | - |
dc.description.abstract | The key to making a practicable hydrogel for pharmaceutical or medical purposes is to endow it with relevant properties, i.e., facile fabrication, gelation time-controllability, and in situ injectability given a firm basis for safety/biocompatibility. Here, the authors describe an in situ gelling, injectable, albumin-cross-linked polyethylene glycol (PEG) hydrogel that was produced using a thiol-maleimide reaction. This hydrogel consists of two biocompatible components, namely, thiolated human serum albumin and 4-arm PEG(20k)-maleimide, and can be easily fabricated and gelled in situ within 60 s by simply mixing its two components. In addition, the gelation time of this system is controllable in the range 15 s to 5 min. This hydrogel hardly interacted with an apoptotic TRAIL protein, ensuring suitable release profiles that maximize therapeutic efficacy. Specifically, tumors (volume: 278.8 mm(3)) in Mia Paca-2 cell-xenografted BALB/c nu/nu mice treated with the TRAIL-loaded HSA-PEG hydrogel were markedly smaller than mice treated with the hydrogel prepared via an amine-N-hydroxysuccinimide reaction or non-treated mice (1275.5 mm(3) and 1816.5 mm(3), respectively). We believe that this hydrogel would be a new prototype of locally injectable sustained-release type anti-cancer agents, and furthermore offers practical convenience for a doctor and universal applicability for a variety of therapeutic proteins. (C) 2015 Elsevier B.V. All rights reserved. | en_US |
dc.description.sponsorship | This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (#2014002133). | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | ELSEVIER SCIENCE BV | en_US |
dc.subject | Hydrogel | en_US |
dc.subject | Polyethylene glycol | en_US |
dc.subject | Albumin | en_US |
dc.subject | In situ formation | en_US |
dc.subject | TNF-related apoptosis-inducing ligand | en_US |
dc.subject | Pancreatic cancer | en_US |
dc.subject | HUMAN SERUM-ALBUMIN | en_US |
dc.subject | LIGAND TRAIL | en_US |
dc.subject | CRYSTAL-STRUCTURE | en_US |
dc.subject | MOUSE SKIN | en_US |
dc.subject | DELIVERY | en_US |
dc.subject | RELEASE | en_US |
dc.subject | DRUG | en_US |
dc.subject | PEGYLATION | en_US |
dc.subject | CHITOSAN | en_US |
dc.subject | CARRIER | en_US |
dc.title | In situ facile-forming PEG cross-linked albumin hydrogels loaded with an apoptotic TRAIL protein | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1016/j.jconrel.2015.07.012 | - |
dc.relation.page | 30-39 | - |
dc.relation.journal | JOURNAL OF CONTROLLED RELEASE | - |
dc.contributor.googleauthor | Kim, IS | - |
dc.contributor.googleauthor | Choi, JS | - |
dc.contributor.googleauthor | Lee, S.H | - |
dc.contributor.googleauthor | Byeon, HJ | - |
dc.contributor.googleauthor | Lee, ES | - |
dc.contributor.googleauthor | Shin, BS | - |
dc.contributor.googleauthor | Choi, HG | - |
dc.contributor.googleauthor | Lee, KC | - |
dc.contributor.googleauthor | Youn, YS | - |
dc.relation.code | 2015002880 | - |
dc.sector.campus | E | - |
dc.sector.daehak | COLLEGE OF PHARMACY[E] | - |
dc.sector.department | DEPARTMENT OF PHARMACY | - |
dc.identifier.pid | hangon | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.